Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cyclotron Produced Isotopes in Biology and Medicine, Project 3: Specific Aim 1A and 1B Effects of Fatty Acid Delivery on Myocardial Metabolism and Function in Type 2 Diabetes (T2DM)

Trial Profile

Cyclotron Produced Isotopes in Biology and Medicine, Project 3: Specific Aim 1A and 1B Effects of Fatty Acid Delivery on Myocardial Metabolism and Function in Type 2 Diabetes (T2DM)

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary) ; Rosiglitazone (Primary) ; Metformin
  • Indications Cardiovascular disorders; Hypertriglyceridaemia; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Aug 2011 Planned end date changed from 1 Jun 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 11 May 2011 Planned end date changed from 1 Jun 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 12 Feb 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top